SiHa Xenograft Model Service for Cervical Cancer

The SiHa xenograft model is a well-established preclinical platform for studying HPV16-positive cervical squamous cell carcinoma, enabling robust evaluation of novel therapeutics, tumor biology, and treatment response in an in vivo setting. Alfa Cytology provides comprehensive SiHa Xenograft Model Services for Cervical Cancer, delivering reproducible tumor growth, integrated pharmacodynamic and pharmacokinetic analysis, and customized study designs to accelerate your preclinical drug development pipeline with scientific rigor and regulatory readiness.

Overview of SiHa Xenograft Model for Cervical Cancer

The SiHa cell line, derived from a human cervical squamous cell carcinoma, is one of the most extensively characterized HPV16-positive cell lines used in preclinical oncology research. When implanted into immunodeficient mice, SiHa cells reliably form subcutaneous or orthotopic xenograft tumors that recapitulate key histopathological and molecular features of human cervical cancer, including HPV16 E6/E7 oncoprotein expression, p53 degradation, and sustained proliferative signaling. These xenografts exhibit consistent tumor take rates and growth kinetics, making them a cornerstone model for evaluating antiviral therapies, chemotherapeutic agents, targeted inhibitors, and immunotherapeutic strategies against HPV-associated malignancies.

SiHa xenografts have been validated across numerous independent studies for their utility in assessing drug efficacy, tumor microenvironment interactions, and biomarker modulation. The model supports both subcutaneous flank implantation for straightforward tumor monitoring and orthotopic cervical implantation for studying site-specific tumor progression and metastatic behavior. Researchers frequently employ SiHa xenografts to investigate mechanisms of cisplatin resistance, radioresponse, angiogenesis inhibition, and the therapeutic potential of HPV-targeted interventions, given the model's faithful maintenance of viral oncogene-driven tumorigenic pathways.

Figure 1. The expression of TRPC6 RNA in HeLa and SiHa cells. *p<0.05 vs HeLa, n=6 (Bai, Li-ping, et al., 2022)

Cell Line Information: SiHa

The SiHa cell line was originally established from a primary squamous cell carcinoma of the cervix from a 55-year-old Asian female patient diagnosed with stage II disease. It is one of the earliest and most widely used HPV16-positive cervical cancer cell lines in preclinical research, extensively characterized for its molecular, genetic, and phenotypic properties.

Our Services

Alfa Cytology offers end-to-end SiHa Xenograft Model Services for Cervical Cancer, encompassing cell line authentication, tumor implantation, in-life monitoring, tumor volume measurement, tissue collection, histopathological analysis, biomarker profiling, and comprehensive study reporting. Our experienced scientific team ensures rigorous quality control, reproducible tumor growth, and flexible study designs tailored to your specific therapeutic modality, whether small molecules, biologics, oncolytic viruses, or combination regimens. We partner with you to generate high-quality preclinical data that supports informed decision-making and accelerates your pipeline toward IND-enabling studies.

Workflow of SiHa Xenograft Model Construction

The construction of a SiHa xenograft model follows a standardized yet customizable workflow designed to ensure reproducible tumor establishment, ethical animal welfare, and robust data generation. Each phase is executed under strict quality assurance protocols with documented standard operating procedures.

1. Cell Preparation and Authentication --- SiHa cells are expanded under optimal culture conditions and authenticated via STR profiling prior to implantation. Mycoplasma testing is performed to ensure cell line purity. Cells are harvested during exponential growth phase using trypsin-EDTA, washed with sterile PBS, and resuspended in serum-free medium or Matrigel at a concentration optimized for tumor take (typically 5x10^6 cells per 100--200 uL injection volume).
2. Animal Selection and Preparation --- Immunodeficient female mice (commonly NOD-SCID, nude, or BALB/c nude, 6--8 weeks old) are acclimatized for at least one week under pathogen-free conditions. Animals are randomized into treatment groups based on body weight, and baseline measurements are recorded. All procedures adhere to institutional animal care and use committee (IACUC) guidelines.
3. Tumor Cell Inoculation --- For subcutaneous models, the SiHa cell suspension is injected into the flank region using a sterile insulin syringe. For orthotopic models, cells are surgically implanted into the cervix or uterine horn under anesthesia to mimic anatomical tumor growth and enable metastasis studies. Tumor take is typically observed within 7--14 days post-inoculation.
4. In-Life Monitoring and Tumor Measurement --- Mice are monitored daily for health status, body weight, and signs of distress. Tumor dimensions are measured twice weekly using digital calipers, and tumor volume is calculated via the modified ellipsoid formula (length x width^2 x 0.5). Tumor growth curves are plotted to assess baseline proliferation kinetics prior to treatment initiation.
5. Treatment Administration --- Once tumors reach a predetermined volume (typically 100--200 mm^3), animals are randomized into vehicle control and treatment arms. Test compounds are administered via the designated route (oral gavage, intraperitoneal, intravenous, or intratumoral) according to the study protocol, with dosing schedules tailored to pharmacokinetic and pharmacodynamic requirements.
6. Endpoint Assessment and Tissue Collection --- At study termination, tumors are excised, weighed, and photographed. Tumor tissue is subdivided for formalin-fixed paraffin-embedded (FFPE) histology, snap-frozen for molecular analysis, and fresh-frozen for pharmacodynamic biomarker assessment. Blood samples may be collected for hematology, clinical chemistry, and exposure analysis.
7. Histopathological and Molecular Analysis --- Tumor sections are subjected to H&E staining for morphology, immunohistochemistry (IHC) for proliferation markers (Ki-67, PCNA), apoptosis markers (cleaved caspase-3, TUNEL), angiogenesis markers (CD31), and HPV-related proteins. Western blot, qPCR, or RNA-seq may be performed on frozen tissues to evaluate pathway modulation.
8. Data Analysis and Reporting --- Tumor growth inhibition (TGI), tumor regression rates, and body weight changes are statistically analyzed. Pharmacodynamic endpoints are correlated with drug exposure data to generate integrated preclinical reports suitable for regulatory documentation and internal decision-making.

Figure 2. SiHa xenograft model construction workflow.

Case Study-SiHa Xenograft Model Development

Alfa Cytology has successfully developed and validated SiHa xenograft models for multiple preclinical therapeutic programs targeting HPV-positive cervical cancer. In a representative engagement, subcutaneous SiHa tumors were established in immunodeficient mice with consistent take rates exceeding 90% and reproducible growth kinetics suitable for efficacy evaluation. Treatment arms demonstrated dose-dependent tumor growth inhibition across multiple candidate modalities, with corresponding pharmacodynamic biomarker modulation confirmed via IHC and molecular profiling. Detailed efficacy data, tumor growth curves, and biomarker results are available upon request under confidentiality agreements. Please contact our scientific team to discuss how these validated models can be adapted for your specific therapeutic candidate.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific expertise, operational excellence, and client-focused flexibility to deliver preclinical tumor model services that meet the highest standards of data quality and regulatory compliance. Our SiHa xenograft program is designed to generate decision-enabling data efficiently and reproducibly.

• Validated, authenticated SiHa cell lines with documented STR profiles and mycoplasma-free certification ensure model integrity from inception.
• Reproducible tumor take rates and growth kinetics across multiple immunodeficient strains provide confidence in study outcomes and statistical power.
• Integrated pharmacodynamic and pharmacokinetic capabilities enable mechanistic understanding and exposure-response correlation within a single service provider.
• Customizable study designs accommodate diverse therapeutic modalities, including combination regimens, dose-escalation schedules, and biomarker-driven endpoints.
• Comprehensive histopathological, IHC, and molecular analysis services deliver multidimensional data packages suitable for IND-enabling documentation.
• Dedicated project management and transparent communication ensure milestone adherence, real-time data access, and adaptive protocol modifications when needed.
• Strict adherence to IACUC guidelines, AAALAC-accredited facilities, and rigorous quality assurance protocols guarantee ethical standards and data reproducibility.

Contact Us

Ready to advance your cervical cancer therapeutic program with a validated SiHa xenograft model? Contact us today to discuss your study requirements, review our capabilities presentation, and receive a customized proposal aligned with your preclinical objectives. Please reach out to us today via our inquiry form or email to learn more about our SiHa Xenograft Model services.

For research use only. Not intended for any clinical use.